GT200200234A - Compuestos cristalinos novedosos - Google Patents

Compuestos cristalinos novedosos

Info

Publication number
GT200200234A
GT200200234A GT200200234A GT200200234A GT200200234A GT 200200234 A GT200200234 A GT 200200234A GT 200200234 A GT200200234 A GT 200200234A GT 200200234 A GT200200234 A GT 200200234A GT 200200234 A GT200200234 A GT 200200234A
Authority
GT
Guatemala
Prior art keywords
crystal compounds
new crystal
organizing
new
transmissant
Prior art date
Application number
GT200200234A
Other languages
English (en)
Inventor
Mark Edward Flanagan
Zheng Jane Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23326961&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200200234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200200234A publication Critical patent/GT200200234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS CRISTALINOS NOVEDOSOS QUE VAN A ACTUAR COMO INHIBIDORES DE QUINASAS, COMO LA ENZIMA JANUS QUINASA 3 (JAK3) POR LO QUE SON DE UTILIDAD EN UNA AMPLIA VARIEDAD DE CASOS, TALES COMO AGENTES INMUNOSUPRESORES PARA TRANSPLANTES DE ORGANOS, XENOTRANSPLANTES, LUPUS, ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, PSORIASIS, DIABETES TIPO I, CANCER, ASMA, ENTRE OTROS DESCRITOS EN LA SOLICITUD.
GT200200234A 2001-12-06 2002-11-21 Compuestos cristalinos novedosos GT200200234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33898401P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
GT200200234A true GT200200234A (es) 2003-06-27

Family

ID=23326961

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200234A GT200200234A (es) 2001-12-06 2002-11-21 Compuestos cristalinos novedosos

Country Status (30)

Country Link
US (2) US6965027B2 (es)
EP (1) EP1451192B1 (es)
JP (1) JP4201135B2 (es)
KR (1) KR100691590B1 (es)
CN (1) CN1325498C (es)
AR (1) AR037635A1 (es)
AT (1) ATE497962T1 (es)
AU (1) AU2002348857B2 (es)
BR (1) BR0214761A (es)
CA (1) CA2469350C (es)
CO (1) CO5580780A2 (es)
CY (1) CY1111311T1 (es)
DE (1) DE60239146D1 (es)
DK (1) DK1451192T3 (es)
ES (1) ES2357942T3 (es)
GT (1) GT200200234A (es)
HK (1) HK1070653A1 (es)
HN (1) HN2002000349A (es)
IL (1) IL161914A0 (es)
MX (1) MXPA04005401A (es)
NO (1) NO20042721L (es)
NZ (1) NZ532366A (es)
PA (1) PA8560201A1 (es)
PE (1) PE20030807A1 (es)
PL (1) PL221493B1 (es)
RU (1) RU2315052C2 (es)
TW (1) TW200300690A (es)
UY (1) UY27567A1 (es)
WO (1) WO2003048162A1 (es)
ZA (1) ZA200404270B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
WO2004047843A1 (en) * 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
WO2006056399A2 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
PT1913000E (pt) 2005-07-29 2012-02-28 Pfizer Prod Inc Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
KR101549876B1 (ko) 2007-06-13 2015-09-03 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
AU2008273804B2 (en) 2007-07-11 2014-07-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CN101772497A (zh) * 2007-07-30 2010-07-07 阿斯利康(瑞典)有限公司 2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈柠檬酸盐的新结晶形式
PL2265607T3 (pl) 2008-02-15 2017-07-31 Rigel Pharmaceuticals, Inc. Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
EP2288610B8 (en) 2008-03-11 2016-10-12 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
BRPI0910921B1 (pt) 2008-04-16 2022-06-21 Portola Pharmaceuticals, Inc Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SI2384326T1 (sl) 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2421867B1 (en) * 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (zh) 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
AU2012241018B2 (en) 2011-04-08 2015-11-12 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
EP3170826A1 (en) 2011-12-15 2017-05-24 ratiopharm GmbH Tofacitinib mono-malate salt
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
UA120834C2 (uk) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням
WO2014097150A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of tofacitinib and intermediates thereof
WO2014102826A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
WO2014195978A2 (en) * 2013-06-05 2014-12-11 Msn Laboratories Limited PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
CN104292231B (zh) * 2013-09-17 2016-11-30 广东东阳光药业有限公司 一种枸橼酸托法替尼的制备方法
WO2015051738A1 (en) * 2013-10-08 2015-04-16 Sunshine Lake Pharma Co., Ltd. Tofacitinib citrate
CN103585126A (zh) * 2013-11-18 2014-02-19 南京艾德凯腾生物医药有限责任公司 一种托法替尼组合物及制备方法
SI3539965T1 (sl) * 2013-12-09 2021-07-30 Unichem Laboratories Limited Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamina
CN104774206A (zh) * 2014-01-14 2015-07-15 江苏柯菲平医药股份有限公司 制备枸橼酸托伐替尼晶型a的新方法
US9260438B2 (en) * 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN104387392B (zh) * 2014-08-22 2016-09-28 中孚药业股份有限公司 制备托法替布的方法
EP3328360A4 (en) * 2015-07-27 2019-01-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
WO2017125417A1 (en) 2016-01-18 2017-07-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tofacitinib as vaccination immune modulator
WO2018095345A1 (zh) * 2016-11-23 2018-05-31 无锡福祈制药有限公司 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
WO2018172821A1 (en) * 2017-03-23 2018-09-27 Phalanx Labs Private Limited Novel tofacitinib addition salts and process for the preparation thereof
CN106967072B (zh) * 2017-04-12 2019-05-03 山东裕欣药业有限公司 一种枸橼酸托法替布晶型化合物及其制备方法
CN109293682A (zh) * 2017-07-25 2019-02-01 重庆医药工业研究院有限责任公司 一种托法替布杂质及其制备方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
CN108484607A (zh) * 2018-03-26 2018-09-04 山东科兴生物制品有限公司 枸橼酸托法替布的新型制备方法
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019213562A1 (en) 2018-05-03 2019-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN109516991B (zh) * 2018-12-29 2020-08-07 山东罗欣药业集团股份有限公司 一种枸橼酸托法替尼晶型化合物及其制备方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
KR102209701B1 (ko) 2019-08-16 2021-01-29 유니셀랩 주식회사 토파시티닙의 신규한 결정형 형태 및 이의 제조방법
EP4057989A1 (en) 2019-11-14 2022-09-21 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN115715194A (zh) 2020-04-04 2023-02-24 辉瑞公司 治疗冠状病毒疾病2019的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
PT938486E (pt) * 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
EP0972197A1 (en) * 1997-03-24 2000-01-19 PHARMACIA & UPJOHN COMPANY Method for identifying inhibitors of jak2/cytokine receptor binding
TR200003719T2 (tr) 1998-06-19 2001-03-21 Pfizer Products Inc. Pirolo[2,3-d]Pirimidin bileşikleri
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
PT1235830E (pt) * 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos

Also Published As

Publication number Publication date
NO20042721L (no) 2004-06-28
UY27567A1 (es) 2003-07-31
TW200300690A (en) 2003-06-16
KR100691590B1 (ko) 2007-03-09
PA8560201A1 (es) 2003-12-10
JP2005511696A (ja) 2005-04-28
US6965027B2 (en) 2005-11-15
NZ532366A (en) 2006-11-30
HN2002000349A (es) 2003-08-20
IL161914A0 (en) 2005-11-20
BR0214761A (pt) 2004-11-09
CN1325498C (zh) 2007-07-11
CY1111311T1 (el) 2015-08-05
DE60239146D1 (de) 2011-03-24
US7803805B2 (en) 2010-09-28
HK1070653A1 (en) 2005-06-24
PL221493B1 (pl) 2016-04-29
AU2002348857B2 (en) 2008-12-04
ZA200404270B (en) 2005-10-26
CO5580780A2 (es) 2005-11-30
US20050159434A1 (en) 2005-07-21
AR037635A1 (es) 2004-11-17
CA2469350A1 (en) 2003-06-12
PL370297A1 (en) 2005-05-16
PE20030807A1 (es) 2003-09-22
JP4201135B2 (ja) 2008-12-24
AU2002348857A1 (en) 2003-06-17
ATE497962T1 (de) 2011-02-15
KR20050044691A (ko) 2005-05-12
RU2315052C2 (ru) 2008-01-20
CA2469350C (en) 2009-09-29
WO2003048162A1 (en) 2003-06-12
EP1451192A1 (en) 2004-09-01
MXPA04005401A (es) 2004-10-11
RU2004117088A (ru) 2005-03-27
DK1451192T3 (da) 2011-04-04
CN1596257A (zh) 2005-03-16
US20030130292A1 (en) 2003-07-10
EP1451192B1 (en) 2011-02-09
ES2357942T3 (es) 2011-05-04

Similar Documents

Publication Publication Date Title
GT200200234A (es) Compuestos cristalinos novedosos
GT200300201A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
GT200200210A (es) Alquinos como inhibidores de metaloproteinasa de matriz
PA8476001A1 (es) COMPUESTOS DE PIRROLO [2,3-d) PIRIMIDINA
ATE449053T1 (de) Indanverbindungen mit negativer dielektrischer anisotropie
GT200000208A (es) Compuestos de pirrolo[2,3-d]pirimidina.
GT200300240A (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos
BRPI0500393A (pt) Processo para a sìntese e forma cristalina de agomelatina e composições farmacêuticas contendo-a
TW200602461A (en) Dibenzofuran, dibenzothiophene and fluorene derivatives
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
TW200516132A (en) Abrasive particles for chemical mechanical polishing
HK1068626A1 (en) Chemical compounds
GT200300097A (es) Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona
TW200734364A (en) Curable composition containing thiol compound
BR0300552A (pt) Misturas de materais de adsorção
CY1109737T1 (el) Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
DE602004024213D1 (en) Aminopropanolderivate
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
UY28350A1 (es) Productos aril-heteroaromaticos, composiciones que los contienen y su utilización
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
MXPA05008099A (es) Productos n-aril-heteroaromaticos, composiciones que los contienen y su utilizacion.
GT200300082A (es) Inhibidores triariloxiariloxipirimidina-2,4,6-triona de metaloproteinasa
ES2193008T1 (es) Gabapentin estable que contiene mas de 20 ppm de un ion de cloro.
CL2009001436A1 (es) Compuestos cristalinos de (1r,2s,3r)-1-(2-isoxazol-3-il)-1himidazol-4-il)butano-1,2,3,4-tetraol; utiles en el tratamiento y/o prevencion de asma, esclerosis multiple, artritis reumatoide, entre otras enfermedades.